Sirnaomics to Present Latest Developments on its GalNAc-Based Liver-Targeting Platforms and GalAhead(TM) Programs at the TIDES USA 2022 Sirnaomics Ltd. May 11, 2022 14:33 HKT/SGT Read More
エーザイ、抗アミロイドβ(Aβ)プロトフィブリル抗体「レカネマブ」について、米国において、迅速承認制度に基づく早期アルツハイマー病に対する生物製剤ライセンス申請の段階的申請を完了 Eisai May 10, 2022 11:00 JST Read More
エーザイ、筋萎縮性側索硬化症(ALS)に対する高用量メコバラミン製剤の医師主導治験の結果を踏まえて、日本における新薬承認申請に向けた作業を開始 Eisai May 10, 2022 11:00 JST Read More
Eisai Completes Rolling Submission to the U.S. FDA for Biologics License Application of Lecanemab for Early Alzheimer's Disease Under the Accelerated Approval Pathway Eisai May 10, 2022 10:23 HKT/SGT Read More
Eisai Initiates Preparation for New Drug Application, Based on the Results of an Investigator-Initiated Clinical Trial of Ultrahigh-Dose Mecobalamin for Amyotrophic Lateral Sclerosis in Japan Eisai May 10, 2022 10:00 HKT/SGT Read More
Novotech收購美國合同研究組織(CRO),拓展全球專業領域 Novotech Health Holdings Pte Ltd May 05, 2022 09:00 HKT/SGT Read More
노보텍, 미국 임상시험수탁기관 인수 - 글로벌 전문성 확대 Novotech Health Holdings Pte Ltd May 05, 2022 09:00 HKT/SGT Read More
Novotech Acquires US CRO NCGS, Expands Global Expertise Novotech Health Holdings Pte Ltd May 05, 2022 09:00 HKT/SGT Read More
Novotech收购美国合同研究组织(CRO),拓展全球专业领域 Novotech Health Holdings Pte Ltd May 05, 2022 09:00 HKT/SGT Read More
Avantor Announces Investment in Manufacturing and Distribution Hub in Singapore to Serve Rapidly Growing Asia Pacific Biopharma Industry Avantor May 05, 2022 04:05 HKT/SGT Read More
Malaysian Genomics Resource Centre Berhad Supports Yayasan Seri Negara's Ramadhan Initiative Malaysian Genomics Resource Centre Bhd Apr 28, 2022 11:30 HKT/SGT Read More
エーザイ、「レカネマブ」の早期アルツハイマー病当事者様に対する長期的健康アウトカムについてシミュレーションを用いた評価結果がNeurology and Therapy誌に掲載 Eisai Apr 28, 2022 10:00 JST Read More
Legend Capital's Portfolio Company Xbiome Acquires Clinical-Stage Program Targeting Ulcerative Colitis Legend Capital Apr 27, 2022 16:09 HKT/SGT Read More
Legend Capital Portfolio: Korean Medical AI Company Lunit to List on KOSDAQ in 2Q2022 Legend Capital Apr 26, 2022 18:07 HKT/SGT Read More
Legend Capital's Co-founded Company Innostellar Biotherapeutics: IRD Gene Therapy Product was Approved for Clinical Trial in China Legend Capital Apr 24, 2022 17:00 HKT/SGT Read More